Zomedica (NYSEAMERICAN:ZOM) Rating Increased to Strong-Buy at Noble Financial

Noble Financial upgraded shares of Zomedica (NYSEAMERICAN:ZOM) to a strong-buy rating in a research report released on Monday,Zacks.com reports. Noble Financial also issued estimates for Zomedica’s Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.05) EPS, Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.

Zomedica Trading Down 6.7 %

Shares of ZOM stock opened at $0.14 on Monday. The company has a market capitalization of $135.23 million, a P/E ratio of -2.30 and a beta of 1.06. Zomedica has a twelve month low of $0.12 and a twelve month high of $0.23.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zomedica stock. Virtu Financial LLC increased its position in Zomedica Corp. (NYSEAMERICAN:ZOM) by 1,585.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 168,773 shares of the company’s stock after purchasing an additional 158,757 shares during the quarter. Virtu Financial LLC’s holdings in Zomedica were worth $25,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.95% of the company’s stock.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.